Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study
Abstract Glioblastoma (GBM), one of the most aggressive brain tumors, has a 5-year survival rate of less than 5%. Current standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, are limited by drug resistance and the blood–brain barrier. Integrating expression quant...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12885-025-13979-3 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|